NewBridge Pharmaceuticals specializes in providing innovative healthcare products to the Middle East, Africa, Turkey and Caspian Regions. NewBridge's regional regulatory capabilities and focused sales and marketing expertise provide biotechnology and pharmaceutical companies with a local partner to commercialize cutting-edge FDA and EMEA-approved therapeutic products. NewBridge will initially focus on the licensing and commercialization of high-value products for diseases with sharply rising regional incidence and prevalence such as diabetes, obesity, cardiovascular and oncologic diseases.
Headquartered in Dubai, UAE, NewBridge was founded in 2007 by Burrill & Company (Burrill), a San Francisco-based Life Science Venture Capital, Private Equity, Merchant Bank and Media firm. Burrill's expansive life science network provides NewBridge unique access to US and European biotechnology companies, drug development and regulatory expertise, as well as strong regional partnerships and investment expertise.
NewBridge Pharmaceuticals has established regulatory, finance, supply chain, pharmacovigilance, and medical affairs capabilities. This integrated strategy and regional focus makes NewBridge the "partner-of-choice" for US, European, and Asian biotech and pharmaceutical companies seeking to access the rapidly expanding markets of the Middle East, Africa, Turkey and Caspian Regions.
| 
